Cargando…
The prognostic value of cardiac troponin for 60 day mortality and major adverse events in COVID-19 patients
BACKGROUND: The variability of coronavirus disease 2019 (COVID-19) illness severity has puzzled clinicians and has sparked efforts to better predict who would benefit from rapid intervention. One promising biomarker for in-hospital morbidity and mortality is cardiac troponin (cTn). METHODS: A retros...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330143/ https://www.ncbi.nlm.nih.gov/pubmed/34358679 http://dx.doi.org/10.1016/j.carpath.2021.107374 |
_version_ | 1783732640604487680 |
---|---|
author | Ruge, Max Gomez, Joanne Michelle D. du Fay de Lavallaz, Jeanne Hlepas, Alexander Rahman, Annas Patel, Priya Lavani, Prutha Nair, Gatha G. Jahan, Nusrat Simmons, J. Alan Rao, Anupama K Williams, Kim A. Volgman, Annabelle Santos Marinescu, Karolina Suboc, Tisha |
author_facet | Ruge, Max Gomez, Joanne Michelle D. du Fay de Lavallaz, Jeanne Hlepas, Alexander Rahman, Annas Patel, Priya Lavani, Prutha Nair, Gatha G. Jahan, Nusrat Simmons, J. Alan Rao, Anupama K Williams, Kim A. Volgman, Annabelle Santos Marinescu, Karolina Suboc, Tisha |
author_sort | Ruge, Max |
collection | PubMed |
description | BACKGROUND: The variability of coronavirus disease 2019 (COVID-19) illness severity has puzzled clinicians and has sparked efforts to better predict who would benefit from rapid intervention. One promising biomarker for in-hospital morbidity and mortality is cardiac troponin (cTn). METHODS: A retrospective study of 1331 adult patients with COVID-19 admitted to the Rush University System in Illinois, USA was performed. Patients without cTn measurement during their admission or a history of end stage renal disease or stage 5 chronic kidney disease were excluded. Using logistic regression adjusted for baseline characteristics, pre-existing comorbidities, and other laboratory markers of inflammation, cTn was assessed as a predictor of 60-day mortality and severe COVID-19 infection, consisting of a composite of 60-day mortality, need for intensive care unit, or requiring non-invasive positive pressure ventilation or intubation. RESULTS: A total of 772 patients met inclusion criteria. Of these, 69 (8.9%) had mild cTn elevation (> 1 to < 2x upper limit of normal (ULN)) and 46 (6.0%) had severe cTn elevation (≥ 2x ULN). Regardless of baseline characteristics, comorbidities, and initial c-reactive protein, lactate dehydrogenase, and ferritin, when compared to the normal cTn group, mild cTn elevation and severe cTn elevation were predictors of severe COVID-19 infection (adjusted OR [aOR] aOR 3.00 [CI: 1.51 – 6.29], P < 0.01; aOR 9.96 [CI: 2.75 – 64.23], P < 0.01, respectively); severe cTn elevation was a predictor of in-hospital mortality (aOR 2.42 [CI: 1.10 – 5.21], P < 0.05) and 60-day mortality (aOR 2.45 [CI: 1.13 – 5.25], P < 0.05). CONCLUSION: In our cohort, both mild and severe initial cTn elevation were predictors of severe COVID-19 infection, while only severe cTn elevation was predictive of 60-day mortality. First cTn value on hospitalization is a valuable longitudinal prognosticator for COVID-19 disease severity and mortality. |
format | Online Article Text |
id | pubmed-8330143 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83301432021-08-03 The prognostic value of cardiac troponin for 60 day mortality and major adverse events in COVID-19 patients Ruge, Max Gomez, Joanne Michelle D. du Fay de Lavallaz, Jeanne Hlepas, Alexander Rahman, Annas Patel, Priya Lavani, Prutha Nair, Gatha G. Jahan, Nusrat Simmons, J. Alan Rao, Anupama K Williams, Kim A. Volgman, Annabelle Santos Marinescu, Karolina Suboc, Tisha Cardiovasc Pathol Original Article BACKGROUND: The variability of coronavirus disease 2019 (COVID-19) illness severity has puzzled clinicians and has sparked efforts to better predict who would benefit from rapid intervention. One promising biomarker for in-hospital morbidity and mortality is cardiac troponin (cTn). METHODS: A retrospective study of 1331 adult patients with COVID-19 admitted to the Rush University System in Illinois, USA was performed. Patients without cTn measurement during their admission or a history of end stage renal disease or stage 5 chronic kidney disease were excluded. Using logistic regression adjusted for baseline characteristics, pre-existing comorbidities, and other laboratory markers of inflammation, cTn was assessed as a predictor of 60-day mortality and severe COVID-19 infection, consisting of a composite of 60-day mortality, need for intensive care unit, or requiring non-invasive positive pressure ventilation or intubation. RESULTS: A total of 772 patients met inclusion criteria. Of these, 69 (8.9%) had mild cTn elevation (> 1 to < 2x upper limit of normal (ULN)) and 46 (6.0%) had severe cTn elevation (≥ 2x ULN). Regardless of baseline characteristics, comorbidities, and initial c-reactive protein, lactate dehydrogenase, and ferritin, when compared to the normal cTn group, mild cTn elevation and severe cTn elevation were predictors of severe COVID-19 infection (adjusted OR [aOR] aOR 3.00 [CI: 1.51 – 6.29], P < 0.01; aOR 9.96 [CI: 2.75 – 64.23], P < 0.01, respectively); severe cTn elevation was a predictor of in-hospital mortality (aOR 2.42 [CI: 1.10 – 5.21], P < 0.05) and 60-day mortality (aOR 2.45 [CI: 1.13 – 5.25], P < 0.05). CONCLUSION: In our cohort, both mild and severe initial cTn elevation were predictors of severe COVID-19 infection, while only severe cTn elevation was predictive of 60-day mortality. First cTn value on hospitalization is a valuable longitudinal prognosticator for COVID-19 disease severity and mortality. Elsevier Inc. 2021 2021-08-03 /pmc/articles/PMC8330143/ /pubmed/34358679 http://dx.doi.org/10.1016/j.carpath.2021.107374 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Ruge, Max Gomez, Joanne Michelle D. du Fay de Lavallaz, Jeanne Hlepas, Alexander Rahman, Annas Patel, Priya Lavani, Prutha Nair, Gatha G. Jahan, Nusrat Simmons, J. Alan Rao, Anupama K Williams, Kim A. Volgman, Annabelle Santos Marinescu, Karolina Suboc, Tisha The prognostic value of cardiac troponin for 60 day mortality and major adverse events in COVID-19 patients |
title | The prognostic value of cardiac troponin for 60 day mortality and major adverse events in COVID-19 patients |
title_full | The prognostic value of cardiac troponin for 60 day mortality and major adverse events in COVID-19 patients |
title_fullStr | The prognostic value of cardiac troponin for 60 day mortality and major adverse events in COVID-19 patients |
title_full_unstemmed | The prognostic value of cardiac troponin for 60 day mortality and major adverse events in COVID-19 patients |
title_short | The prognostic value of cardiac troponin for 60 day mortality and major adverse events in COVID-19 patients |
title_sort | prognostic value of cardiac troponin for 60 day mortality and major adverse events in covid-19 patients |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330143/ https://www.ncbi.nlm.nih.gov/pubmed/34358679 http://dx.doi.org/10.1016/j.carpath.2021.107374 |
work_keys_str_mv | AT rugemax theprognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients AT gomezjoannemichelled theprognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients AT dufaydelavallazjeanne theprognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients AT hlepasalexander theprognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients AT rahmanannas theprognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients AT patelpriya theprognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients AT lavaniprutha theprognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients AT nairgathag theprognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients AT jahannusrat theprognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients AT simmonsjalan theprognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients AT raoanupamak theprognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients AT williamskima theprognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients AT volgmanannabellesantos theprognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients AT marinescukarolina theprognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients AT suboctisha theprognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients AT rugemax prognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients AT gomezjoannemichelled prognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients AT dufaydelavallazjeanne prognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients AT hlepasalexander prognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients AT rahmanannas prognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients AT patelpriya prognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients AT lavaniprutha prognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients AT nairgathag prognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients AT jahannusrat prognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients AT simmonsjalan prognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients AT raoanupamak prognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients AT williamskima prognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients AT volgmanannabellesantos prognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients AT marinescukarolina prognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients AT suboctisha prognosticvalueofcardiactroponinfor60daymortalityandmajoradverseeventsincovid19patients |